COMMUNIQUÉS West-GlobeNewswire

ProDentim Reviews (EXPOSED): Why 75,000+ Americans Are Replacing Mouthwash with This ProDentim Chewable Tablet
29/03/2025
Discover the Oral Probiotic That’s Reshaping Dental Health—Backed by 75,000+ Users and Groundbreaking Science VANCOUVER, WA, March 29, 2025 (GLOBE NEWSWIRE) -- ProDentim reviews In the fast-growing realm of oral health [...]
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
29/03/2025
Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial 1 . Data were presented [...]
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)
29/03/2025
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile – – Lorundrostat is a [...]
NeuroQuiet Reviews (Complaints & Side Effects): Buyers Reveal Unexpected Truths Behind Its Real Effectiveness & Safety
29/03/2025
VANCOUVER, WA, March 29, 2025 (GLOBE NEWSWIRE) -- NeuroQuiet Reviews In a market flooded with hearing supplements and cognitive enhancers, NeuroQuiet has quickly risen to prominence. Over 30,000+ users have already [...]
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
29/03/2025
Ozempic ® improved maximum walking distance by 13% vs placebo in adults with type 2 diabetes and peripheral artery disease (PAD) in the phase 3 STRIDE trial 1 . Data were presented at the American College of Cardiology' [...]
Best Legal Steroids for Bulking and Muscle Growth 2025 - Buy Steroid Alternatives From CrazyBulk
29/03/2025
NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- Use D-Bal to pack on serious muscle and boost your strength in 2025. Using the best legal steroid for bulking and muscle growth can make all the difference in achieving [...]
Legal Steroids For Muscle Growth 2025: Best Steroids For (Bodybuilding & Bulking) By CrazyBulk in USA
29/03/2025
NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- While there is a huge range of steroids available in the market, it is very difficult to know which can work the best for your muscle growth . Choosing the right steroids is [...]
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
29/03/2025
SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
29/03/2025
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated approach to [...]
Curium finalise l’acquisition de Monrol, axée sur le net renforcement de sa capacité de production de lutécium-177 et de son empreinte PET
29/03/2025
Affirmation de son leadership dans la production de l’isotope lutétium-177 Renforcement de son expertise en R&D et consolidation de son pipeline innovant Extension de sa couverture géographique et de sa chaîne d’ [...]
Safety Shot, Inc. Announces Record Date for Spin-Off and Distribution of Shares Common Stock of Caring Brands, Inc. - Updated
29/03/2025
JUPITER, FL, March 28, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (the “Company” or “Safety Shot”), today announced that the record date for the spin-off and distribution of shares of common stock, par [...]
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress
28/03/2025
$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as [...]
Traws Pharma Announces Management Updates
28/03/2025
Werner Cautreels, PhD, to retire as CEO, while continuing as a Board Member Iain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. ( [...]
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
28/03/2025
New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging significantly refines [...]
Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX
28/03/2025
FARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced its intention to voluntarily delist its common stock from The New York Stock Exchange (“NYSE [...]
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
28/03/2025
– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2 Data of Olvi-Vec in [...]
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
28/03/2025
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent protection with as few [...]
Communiqué de presse : Qfitlia – premier médicament approuvé aux États-Unis pour le traitement des hémophilies A ou B, avec ou sans inhibiteurs
28/03/2025
Qfitlia – premier médicament approuvé aux États-Unis pour le traitement des hémophilies A ou B, avec ou sans inhibiteurs Le Qfitlia (fitusiran), premier médicament abaissant le taux d’antithrombine pour le traitement de [...]
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
28/03/2025
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business [...]

Pages